FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial

PURPOSE: 5-Fluorouracil/leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) plus bevacizumab is more effective than doublets plus bevacizumab as first-line therapy for metastatic colorectal cancer, but is not widely used because of concerns about toxicity and lack of predictive biomarkers. This study wa...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:ESMO Open
Huvudupphovsmän: Aranda, Enrique, Viéitez, Jose Maria, Gómez-España, Auxiliadora, Gil Calle, Silvia, Salud-Salvia, Antonieta, Graña, Begoña, Garcia-Alfonso, Pilar, Rivera, Fernando, Quintero-Aldana, Guillermo Alfonso, Reina-Zoilo, Juan José, González-Flores, Encarnación, Salgado Fernández, Mercedes, Guillén‑Ponce, Carmen, Garcia-Carbonero, Rocio, Safont, María José, La Casta Munoa, Adelaida, García-Paredes, Beatriz, López López, Rafael, Sastre, Javier, Díaz-Rubio, Eduardo
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Publishing Group 2020
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7640586/
https://ncbi.nlm.nih.gov/pubmed/33148620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000944
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk